AlMansour Alhanouf M, Almutairi Nada A, Abdul Hafiez Nafisa, Alkaiyat Mohammad
Oncology, King Saud Bin Abdulaziz University for Health Sciences College of Medicine, Riyadh, SAU.
Oncology, Ministry of National Guard Health Affairs (MNGHA), Riyadh, SAU.
Cureus. 2024 Aug 15;16(8):e66927. doi: 10.7759/cureus.66927. eCollection 2024 Aug.
The approach to manage breast cancer has undergone a significant transformation, leading to longer survival rates. However, there is still a rise in metastasis occurring in less common locations such as the orbit. We report the case of a 40-year-old female diagnosed with luminal A, left-side breast cancer, back in September 2020. She presented with de novo metastatic diseases to the liver, bone, lung, and orbit. She received palliative radiation therapy (RT) to the orbit at the dose of 25 Gray (Gy) in five fractions, and follow-up brain magnetic resonance imaging (MRI) indicated a positive response to treatment with a slight reduction in the size of the left infraorbital lesion. Systemic treatment was started with hormonal therapy fulvestrant and luteinizing hormone-releasing hormone (LHRH), leuprolide, accompanied by palbociclib. As the incidence of ocular metastasis from breast cancer increases, oncologists need to be vigilant about symptoms and use appropriate diagnostic techniques.
乳腺癌的治疗方法已经历了重大变革,使得生存率得以提高。然而,在诸如眼眶等不太常见的部位发生转移的情况仍在增加。我们报告一例40岁女性病例,该患者于2020年9月被诊断为左侧乳腺管腔A型乳腺癌。她初诊时就已出现肝脏、骨骼、肺部和眼眶的转移病灶。她接受了眼眶姑息性放射治疗(RT),剂量为25格雷(Gy),分五次进行,后续的脑部磁共振成像(MRI)显示治疗有积极效果,左侧眶下病变大小略有缩小。全身治疗采用了激素疗法氟维司群和促黄体生成激素释放激素(LHRH)、亮丙瑞林,并联合哌柏西利。随着乳腺癌眼部转移发病率的增加,肿瘤学家需要对症状保持警惕并采用适当的诊断技术。